<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00657865</url>
  </required_header>
  <id_info>
    <org_study_id>Ram_Gep_1</org_study_id>
    <secondary_id>2007-007276-41</secondary_id>
    <nct_id>NCT00657865</nct_id>
  </id_info>
  <brief_title>Gene Expression Profiling in Skeletal Muscle of Healthy Subjects Treated With Ramipril</brief_title>
  <official_title>Gene Expression Profiling in Skeletal Muscle of Healthy Subjects Treated With Ramipril</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project investigates the effect of ACE-inhibition on cellular metabolism by gene&#xD;
      expression profiling of human muscle tissue, obtained by biopsy prior to and after ramipril&#xD;
      intake.&#xD;
&#xD;
      This should contribute to our understanding of the pathomechanisms involved in diabetes and&#xD;
      the clinical effect of ACE-inhibition on patients with diabetes/metabolic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Genome-wide gene expression measurements in skeletal muscle at baseline and in response to ramipril intake.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ramipril</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ramipril</intervention_name>
    <description>oral intake</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  Healthy defined as absence of relevant disease&#xD;
&#xD;
          -  Caucasian&#xD;
&#xD;
          -  Aged 18-45 years&#xD;
&#xD;
          -  BMI: 18-28 kg/m2&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Blood pressure between 110/45 and &lt;140/90 (twice at screening)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of renal artery stenosis&#xD;
&#xD;
               -  angioneurotic edema&#xD;
&#xD;
               -  psoriasis&#xD;
&#xD;
               -  relevant renal diseases&#xD;
&#xD;
          -  RR at screening &lt; 110/45 mmHg.&#xD;
&#xD;
          -  Diabetes, history of hypertension, RR &gt; 140/90 at screening, cardiovascular disease&#xD;
&#xD;
          -  Known Diabetes mellitus of parents&#xD;
&#xD;
          -  HIV or Hepatitis B/C positive virology&#xD;
&#xD;
          -  Allergy or hypersensitivity against ACE-inhibitors / ramipril or to xylocain&#xD;
&#xD;
          -  Contraindications against the use of the drug according to the SmPC, history of&#xD;
             angioedema&#xD;
&#xD;
          -  Any drug intake 3 weeks prior to first study day&#xD;
&#xD;
          -  History of excessive bleeding tendency / hemophilia&#xD;
&#xD;
          -  Presence of relevant illness within the last 3 weeks&#xD;
&#xD;
          -  Suspected non-compliance with study instructions and life-style requirements&#xD;
&#xD;
          -  Alcohol or drug abuse&#xD;
&#xD;
          -  Blood/Plasma donation within 4 weeks prior to study day&#xD;
&#xD;
          -  Previous exposure to antihypertensive drugs, ACE-inhibitors, in particular ramipril&#xD;
&#xD;
          -  Current smoking (any quantity), (at least 6 months of non-smoking required)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Mueller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna, Dep. of Clinical Pharmacology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University Vienna, Department of Clinical Pharacology</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>April 8, 2008</study_first_submitted>
  <study_first_submitted_qc>April 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2008</study_first_posted>
  <last_update_submitted>August 19, 2011</last_update_submitted>
  <last_update_submitted_qc>August 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Markus Mueller</investigator_full_name>
    <investigator_title>Prof. Dr</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramipril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

